NEW YORK (TheStreet) -- It appears that Gilead Sciences (GILD) - Get Report is continuing to dominate in hepatitis C, Leerink analysts said, reiterating their "outperform" rating on the stock. 

Shares are rising by 0.04% to $92.01 on Thursday afternoon.

This comes after the firm went over abstracts for the European Association for the Study of the Liver (EASL) conference which will take place on April 13 to 17. 

Analysts said their bullish outlook is largely due to the company's success of its anti-viral programs, including the "significant" cash generation of its HCV franchise. 

Ahead of the meeting in Barcelona, the firm believes the discussions about the treatment and management of liver diseases will likely have a positive impact on the company's future. 

Based in Foster City, CA, Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific.

Separately, TheStreet Ratings currently has a "Buy" rating on the stock with a letter grade of B.

The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles' author.

You can view the full analysis from the report here: GILD

Image placeholder title